Dimensional Fund Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

Dimensional Fund Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.53M	Buy	1,365,384 +63,720	+5%	+$156K	﹤0.01%	2694
2026 Q1	$2.77M	Buy	1,301,664 +444,649	+52%	+$1.06M	﹤0.01%	2636
2025 Q4	$2.08M	Buy	857,015 +401,145	+88%	+$1.42M	﹤0.01%	2732
2025 Q3	$1.73M	Hold	455,870	–	–	﹤0.01%	2801
2025 Q2	$1.13M	Sell	455,870 -116,600	-20%	-$225K	﹤0.01%	2867
2025 Q1	$888K	Sell	572,470 -88,966	-13%	-$187K	﹤0.01%	2905
2024 Q4	$1.42M	Buy	661,436 +405,579	+159%	+$1.16M	﹤0.01%	2862
2024 Q3	$1.11M	Buy	255,857 +55,813	+28%	+$304K	﹤0.01%	2893
2024 Q2	$932K	Buy	200,044 +88,378	+79%	+$474K	﹤0.01%	2922
2024 Q1	$566K	Buy	111,666 +1,054	+1%	+$4.25K	﹤0.01%	3025
2023 Q4	$312K	Buy	110,612 +58,354	+112%	+$137K	﹤0.01%	3126
2023 Q3	$150K	Buy	52,258 +35,171	+206%	+$130K	﹤0.01%	3258
2023 Q2	$86.3K	Sell	17,087 -8,833	-34%	-$18K	﹤0.01%	3345
2023 Q1	$49K	Buy	+25,920	New	+$59.6K	﹤0.01%	3386
2022 Q3	$101K	Buy	+60,046	New	+$185K	﹤0.01%	3326

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Dimensional Fund Advisors's BDTX Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Black Diamond Therapeutics (BDTX) stake by 4.9% in Q2 2026, buying an estimated $156K and bringing the position to 1,365,384 shares worth $2.53M. The position accounts for ﹤0.01% of the portfolio, ranked #2694.

Dimensional Fund Advisors first reported a position in BDTX in Q3 2022 and has held it in 15 quarters since. The position peaked at $2.77M in Q1 2026. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

Dimensional Fund Advisors held 1,365,384 shares of Black Diamond Therapeutics worth $2.53M as of Q2 2026.
Dimensional Fund Advisors bought 63,720 Black Diamond Therapeutics shares in Q2 2026, an estimated $156K.
Black Diamond Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2694 holding.
Dimensional Fund Advisors first reported a position in Black Diamond Therapeutics in Q3 2022 and has held it in 15 quarters since.
Dimensional Fund Advisors's Black Diamond Therapeutics position peaked at $2.77M in Q1 2026.
96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.